1. 1. Krushkal J, Silvers T, Reinhold WC, Sonkin D, Vural S, Connelly J, et al. (2020) Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Clinical Epigenetics, 12(1): 93. [DOI:10.1186/s13148-020-00876-8] [PMID] []

2. Yu S, Sha H, Qin X, Chen Y, Li X, Shi M, et al. (2020) EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene, 39(13): 2643-2657. [DOI:10.1038/s41388-020-1182-y] [PMID]

3. Agustoni F, Suda K, Yu H, Ren S, Rivard CJ, Ellison K, et al. (2019) EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer treatment reviews, 72: 15-27. [DOI:10.1016/j.ctrv.2018.08.002] [PMID]

4. Wu H, Li L, Yang J, Yang ZM (2021) Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis. The Clinical Respiratory Journal, 15(2): 187-195. [DOI:10.1111/crj.13283] [PMID]

5. He Y-P, Li L-X, Tang J-X, Yi L, Zhao Y, Zhang H-W, et al. (2019) HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis. Medicine, 98(39): e17198. [DOI:10.1097/MD.0000000000017198] [PMID] []

6. Lu GJ, Shao CJ, Zhang Y, Wei YY, Xie WP, Kong H (2017) Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer. Oncotarget, 8(30): 49217. [DOI:10.18632/oncotarget.17455] [PMID] []

7. Manolov V, Marinov B, Vasilev V, Andreeva A (2011) HE4--a new tumor marker for ovarian cancer. Akusherstvo i ginekologiia, 50: 11-5.

8. Montagnana M, Danese E, Giudici S, Franchi M, Guidi G, Plebani M, et al. (2011) HE4 in ovarian cancer: from discovery to clinical application. Advances in clinical chemistry, 55: 2. [DOI:10.1016/B978-0-12-387042-1.00001-0] [PMID]

9. Wang X, Fan Y, Wang J, Wang H, Liu W (2014) Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer. Tumor Biology, 35: 6847-6853. [DOI:10.1007/s13277-014-1943-8] [PMID]

10. Stiekema A, Boldingh Q, Korse C, Van Der Noort V, Boot H, Van Driel W, et al. (2015) Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic oncology, 136(3): 562-566. [DOI:10.1016/j.ygyno.2014.12.037] [PMID]

11. Nagy Jr B, Bhattoa HP, Steiber Z, Csobán M, Szilasi M, Méhes G, et al. (2014) Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clinical Chemistry and Laboratory Medicine (CCLM), 52(11): 1639-1648. [DOI:10.1515/cclm-2014-0041] [PMID]

12. Hertlein L, Stieber P, Kirschenhofer A, Fürst S, Mayr D, Hofmann K, et al. (2012) Human epididymis protein 4 (HE4) in benign and malignant diseases. Clinical Chemistry and Laboratory Medicine (CCLM), 50(12): 2181-2188. [DOI:10.1515/cclm-2012-0097] [PMID]

13. Lassalle P, Molet S, Janin A, Van der Heyden J, Tavernier J, Fiers W, et al. (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. Journal of Biological Chemistry, 271(34): 20458-20464. [DOI:10.1074/jbc.271.34.20458] [PMID]

14. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al. (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clinical cancer research, 12(15): 4575-4582. [DOI:10.1158/1078-0432.CCR-06-0185] [PMID]

15. Huang X, Chen C, Wang X, Zhang JY, Ren BH, Ma DW, et al. (2016) Prognostic value of endocan expression in cancers: evidence from meta-analysis. OncoTargets and therapy, 13(9): 6297-6304. [DOI:10.2147/OTT.S110295] [PMID] []

16. Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, et al. (2011) ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino acids, 40: 1003-1013. [DOI:10.1007/s00726-010-0729-6] [PMID]

17. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al. (2010) Vascular endocan (ESM‐1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology, 56(2): 180-187. [DOI:10.1111/j.1365-2559.2009.03458.x] [PMID]

18. Ji NY, Kim YH, Jang YJ, Kang YH, Lee CI, Kim JW, et al. (2010) Identification of endothelial cell‐specific molecule‐1 as a potential serum marker for colorectal cancer. Cancer science, 101(10): 2248-2253. [DOI:10.1111/j.1349-7006.2010.01665.x] [PMID] []

19. Jiang H, Fu X, Chen Y (2015) Serum level of endothelial cell-specific molecule-1 and prognosis of colorectal cancer. Genet Mol Res, 14(2): 5519-5526. [DOI:10.4238/2015.May.25.3] [PMID]

20. Lv Z, Fan Y, Chen H, Zhao D (2014) Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer. Tumor Biology, 35: 10497-10502. [DOI:10.1007/s13277-014-2319-9] [PMID]

21. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. (2022) Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20(5): 497-530. [DOI:10.6004/jnccn.2022.0025] [PMID]

22. Jiang J, Li Z, Zhang F, Li H, Li R, Qiu Q, et al. (2021) Efficacy and safety of Shen-Ling-Bai-Zhu-San combined with chemotherapy for lung cancer: A protocol for systematic review and meta-analysis. Medicine, 100(6): e24590. https://doi.org/10.1097/MD.0000000000024590 [DOI:10.37766/inplasy2021.1.0025] [PMID] []

23. Yang Y, Luo H, Zheng X, Ge H (2021) The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology, 23: 1117-1127. [DOI:10.1007/s12094-020-02502-8] [PMID]

24. Germonpré P, Van den Wyngaert T (2019) Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. Plos one, 14(4): e0215135. [DOI:10.1371/journal.pone.0215135] [PMID] []

25. Lv M, Wang F, Wang X, Zhang C (2019) Diagnostic value of human epididymis protein 4 in malignant pleural effusion in lung cancer. Cancer Biomarkers, 26(4): 523-528. [DOI:10.3233/CBM-190840] [PMID]

26. Li Y, Li M, Zhang Y, Zhou J, Jiang L, Yang C, et al. (2021) Age‐stratified and gender‐specific reference intervals of six tumor markers panel of lung cancer: A geographic‐based multicenter study in China. Journal of Clinical Laboratory Analysis, 35(6): e23816. [DOI:10.1002/jcla.23816] [PMID] []

27. Liu J, Han L, Jiao Z (2021) The diagnostic value of human epididymis protein 4 for endometrial cancer is moderate. Scientific reports, 11(1): 575. [DOI:10.1038/s41598-020-79960-1] [PMID] []

28. Lan WG, Hao YZ, Xu DH, Wang P, Zhou YL, Ma LB (2016) Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer. Clinical and Translational Oncology, 18(4): 375-380. [DOI:10.1007/s12094-015-1375-y] [PMID]

29. Mo D, He F (2018) Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer. Clinical Laboratory, 64(9): 1421-1428. [DOI:10.7754/Clin.Lab.2018.180222] [PMID]

30. Pan KF, Lee WJ, Chou CC, Yang YC, Chang YC, Chien MH, et al. (2021) Direct interaction of β‐catenin with nuclear ESM1 supports stemness of metastatic prostate cancer. The EMBO journal, 40(4): e105450. [DOI:10.15252/embj.2020105450] [PMID] []

31. Lu GJ, Shao CJ, Zhang Y, Wei YY, Xie WP, Kong H (2017) Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer. Oncotarget, 8(30): 49217-49223. [DOI:10.18632/oncotarget.17455] [PMID] []

32. Yang WE, Hsieh MJ, Lin CW, Kuo CY, Yang SF, Chuang CY, et al. (2017) Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression. Int J Med Sci, 14(11): 1094-100. [DOI:10.7150/ijms.20414] [PMID] []

33. Wu H, Wang Q, Liu Q, Zhang Q, Huang Q, Yu Z (2020) The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer. Clinical laboratory, 66(3): 190533. [DOI:10.7754/Clin.Lab.2019.190533] [PMID]

34. Yang J, Lin L, Jiang W, Wu J, Lin X (2020) Early diagnosis of lung cancer in the elderly using four tumor markers and serum ferritin for better surgical management. Asian Journal of Surgery, 43(11): 1088-1089. [DOI:10.1016/j.asjsur.2020.07.025] [PMID]